Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population.

IF 2.6 Q3 IMMUNOLOGY

International Journal of Inflammation Pub Date : 2020-09-08 eCollection Date: 2020-01-01 DOI:10.1155/2020/9476326

L Akhmaltdinova, V Sirota, V Zhumaliyeva, D Babenko, I Kadyrova, Z Tauesheva, D Taizhanova, A Ibraeva, M Maratkyzy, A Turmukhambetova

{"title":"Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population.","authors":"L Akhmaltdinova, V Sirota, V Zhumaliyeva, D Babenko, I Kadyrova, Z Tauesheva, D Taizhanova, A Ibraeva, M Maratkyzy, A Turmukhambetova","doi":"10.1155/2020/9476326","DOIUrl":null,"url":null,"abstract":"Colorectal cancer is a type of oncopathology widespread in Kazakhstan. The genetic component, as well as the possible etiopathogenetic mechanisms, is widely studied. One of the most promising areas is the study of diagnostic and prognostic possibilities of inflammatory biomarkers in patients with different degrees of tumor differentiation. The following biomarkers were included in the study panel: stem cell factor (SCF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF2), interleukin 6 (IL6), interleukin 8 (IL8), macrophage migration inhibitory factor (MIF), soluble Fas (SFAS), soluble Fas ligand (sFASL), transforming growth factor β (TGF), tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and programmed death ligand 1 (PD-L1). The data of our study show that most of the basic proinflammatory cytokines are involved in the systemic process and their levels do not depend on the level of tissue differentiation. Serum PD-L1 has shown itself to be a promising marker for tumor growth, which depends on the degree of differentiation.","PeriodicalId":14004,"journal":{"name":"International Journal of Inflammation","volume":"2020 ","pages":"9476326"},"PeriodicalIF":2.6000,"publicationDate":"2020-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9476326","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Inflammation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/9476326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Colorectal cancer is a type of oncopathology widespread in Kazakhstan. The genetic component, as well as the possible etiopathogenetic mechanisms, is widely studied. One of the most promising areas is the study of diagnostic and prognostic possibilities of inflammatory biomarkers in patients with different degrees of tumor differentiation. The following biomarkers were included in the study panel: stem cell factor (SCF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF2), interleukin 6 (IL6), interleukin 8 (IL8), macrophage migration inhibitory factor (MIF), soluble Fas (SFAS), soluble Fas ligand (sFASL), transforming growth factor β (TGF), tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and programmed death ligand 1 (PD-L1). The data of our study show that most of the basic proinflammatory cytokines are involved in the systemic process and their levels do not depend on the level of tissue differentiation. Serum PD-L1 has shown itself to be a promising marker for tumor growth, which depends on the degree of differentiation.

查看原文本刊更多论文

哈萨克斯坦人群结直肠癌的炎性血清生物标志物

结直肠癌是哈萨克斯坦广泛存在的一种肿瘤病理。遗传成分，以及可能的发病机制，被广泛研究。其中一个最有前途的领域是研究炎症生物标志物在不同程度肿瘤分化患者中的诊断和预后可能性。以下生物标志物被纳入研究小组:干细胞因子(SCF)、血管内皮生长因子(VEGF)、成纤维细胞生长因子(FGF2)、白细胞介素6 (IL6)、白细胞介素8 (IL8)、巨噬细胞迁移抑制因子(MIF)、可溶性Fas (SFAS)、可溶性Fas配体(sFASL)、转化生长因子β (TGF)、肿瘤坏死因子(TNF)、TNF相关的凋亡诱导配体(TRAIL)和程序性死亡配体1 (PD-L1)。我们的研究数据表明，大多数基础促炎细胞因子参与了系统性过程，其水平不依赖于组织分化水平。血清PD-L1已被证明是肿瘤生长的一个有希望的标志物，这取决于分化程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊